Flputnam Investment Management Co. Makes New Investment in Dyne Therapeutics, Inc. $DYN

Key Points

• Flputnam Investment Management initiated a Dyne Therapeutics stake of 52,975 shares valued at approximately $1.18 million. Institutional investors collectively own 96.68% of DYN, with several major funds increasing their positions.
• Analyst sentiment remains generally positive, with a consensus rating of “Moderate Buy” and an average price target of $34.42. Price targets range from $35 to $50, although one firm downgraded the stock to “strong sell.”
• DYN shares opened at $26.15, near their 12-month high, but the company reported a larger-than-expected quarterly loss of $1.08 per share versus the $0.75 consensus estimate. Insider selling has also been substantial, including a director’s $54 million sale under a Rule 10b5-1 plan.

Flputnam Investment Management Co. purchased a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The fund purchased 52,975 shares of the company's stock, valued at approximately $1,177,000.

A number of other large investors also recently made changes to their positions in DYN. T. Rowe Price Investment Management Inc. lifted its position in Dyne Therapeutics by 523.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company's stock worth $343,085,000 after buying an additional 14,727,667 shares during the period. Vanguard Group Inc. grew its stake in Dyne Therapeutics by 14.9% during the fourth quarter. Vanguard Group Inc. now owns 11,215,565 shares of the company's stock worth $219,376,000 after buying an additional 1,455,151 shares during the period. State Street Corp boosted its position in Dyne Therapeutics by 27.0% during the 4th quarter. State Street Corp now owns 6,692,745 shares of the company's stock worth $130,910,000 after purchasing an additional 1,423,828 shares during the period. Adage Capital Partners GP L.L.C. boosted its position in Dyne Therapeutics by 45.5% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,172,000 shares of the company's stock worth $101,164,000 after purchasing an additional 1,618,000 shares during the period. Finally, Orbis Allan Gray Ltd acquired a new stake in Dyne Therapeutics in the 4th quarter valued at $93,926,000. Hedge funds and other institutional investors own 96.68% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on DYN shares. Royal Bank Of Canada boosted their price objective on Dyne Therapeutics from $30.00 to $35.00 and gave the stock an "outperform" rating in a research note on Thursday, July 30th. HC Wainwright reiterated a "buy" rating and issued a $50.00 target price on shares of Dyne Therapeutics in a research note on Monday. Morgan Stanley dropped their target price on Dyne Therapeutics from $47.00 to $45.00 and set an "overweight" rating on the stock in a report on Friday, July 31st. Wall Street Zen lowered Dyne Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 1st. Finally, TD Cowen assumed coverage on Dyne Therapeutics in a report on Friday, June 26th. They issued a "buy" rating for the company. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $34.42.

Dyne Therapeutics Stock Performance

Shares of DYN stock opened at $26.15 on Tuesday. Dyne Therapeutics, Inc. has a 12 month low of $11.65 and a 12 month high of $27.31. The company has a debt-to-equity ratio of 0.28, a current ratio of 12.02 and a quick ratio of 12.02. The firm has a market capitalization of $4.88 billion, a P/E ratio of -7.85 and a beta of 1.07. The company's fifty day moving average price is $23.02 and its two-hundred day moving average price is $19.55.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its earnings results on Thursday, July 30th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.33). On average, research analysts anticipate that Dyne Therapeutics, Inc. will post -3.37 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Dyne Therapeutics news, CFO Erick Lucera sold 2,362 shares of the stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $20.37, for a total transaction of $48,113.94. Following the transaction, the chief financial officer directly owned 121,563 shares in the company, valued at $2,476,238.31. This represents a 1.91% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Jason P. Rhodes sold 2,160,516 shares of the stock in a transaction on Friday, August 14th. The shares were sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the transaction, the director owned 428,946 shares in the company, valued at $10,723,650. This trade represents a 83.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have acquired 9,000 shares of company stock valued at $156,800 and have sold 4,139,196 shares valued at $99,449,852. 9.46% of the stock is owned by company insiders.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source